DK2521555T3 - Fremgangsmåder og sammensætninger til forøgelse af følsomheden over for tyrosinkinasehæmmere - Google Patents
Fremgangsmåder og sammensætninger til forøgelse af følsomheden over for tyrosinkinasehæmmere Download PDFInfo
- Publication number
- DK2521555T3 DK2521555T3 DK10832418.7T DK10832418T DK2521555T3 DK 2521555 T3 DK2521555 T3 DK 2521555T3 DK 10832418 T DK10832418 T DK 10832418T DK 2521555 T3 DK2521555 T3 DK 2521555T3
- Authority
- DK
- Denmark
- Prior art keywords
- mir
- egfr
- cancer
- mirna
- tyrosine kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (6)
1. miR-7-miRNA eller en prækursor deraf, hvor prækursoren er valgt fra gruppen bestående af hsa-miR-7-1, hsa-miR-7-2 og hsa-miR-7-3, i kombination med en tyrosinkinasehæmmer, der er selektiv eller specifik for EGFR, til anvendelse ved behandling af cancer hos et individ, hvor cancercellerne udtrykker eller overudtrykker EGFR, og eventuelt hvor canceren udviser resistens over for tyrosinkinasen ved fravær af behandling. 2. miR-7-miRNA eller prækursor deraf i kombination med en tyrosinkinasehæmmer, der er selektiv eller specifik for EGFR, til anvendelse ifølge krav 1, hvor den EGFR-udtrykkende cancertype er valgt fra gruppen bestående af hoved- og halscancer, glioblastom, pankreascancer, koloncancer, kolorektal cancer, næsesvælgcancer, livmodercancer, livmoderhalscancer, øso-faguscancer, mavecancer, nyrecancer, blærecancer, lungecancer, herunder ikke-småcellet lungecancer, prostatacancer, brystcancer, levercancer, neu-roblastom eller melanom. 3. miR-7-miRNA eller prækursor deraf i kombination med en tyrosinkinasehæmmer, der er selektiv eller specifik for EGFR til anvendelse ifølge krav 1 eller 2, hvor tyrosinkinasehæmmeren er valgt fra gruppen bestående af erlo-tinib og AG1478. 4. miR-7-miRNA eller prækursor deraf i kombination med en tyrosinkinasehæmmer, der er selektiv eller specifik for EGFR, til anvendelse ifølge et af kravene 1 til 3, hvor miR-7-miRNA'et er hsa-miR-7 og omfatter nukleotidse-kvensen ifølge SEQ ID NO:1. 5. miR-7-miRNA eller prækursor deraf i kombination med en tyrosinkinasehæmmer, der er selektiv eller specifik for EGFR, til anvendelse ifølge et af kravene 1 til 3, hvor miR-7-miRNA-prækursoren omfatter en sekvens ifølge en af SEQ ID NO:2 til 4. 6. miR-7-miRNA eller prækursor deraf i kombination med en tyrosinkinasehæmmer, der er selektiv eller specifik for EGFR, til anvendelse ifølge et af kravene 1 til 5, hvor tyrosinkinasehæmmeren og miRNA'et administreres i en enkelt sammensætning, formuleret sammen med farmaceutisk acceptable bærere, excipienser eller adjuvanser. 7. miR-7-miRNA eller prækursor deraf i kombination med en tyrosinkinase-hæmmer, der er selektiv eller specifik for EGFR, til anvendelse ifølge et af kravene 1 til 5, hvor tyrosinkinasehæmmeren og miRNA'et administreres i separate sammensætninger, eventuelt hvor miRNA'et administreres før tyro-sinekinasehæmmeren. 8. miR-7-miRNA eller prækursor deraf i kombination med en tyrosinkinase-hæmmer, der er selektiv eller specifik for EGFR, til anvendelse ifølge et af kravene 1 til 7, hvor behandlingen omfatter forebyggelse eller reduktion af tumorvækst, cancermetastaser eller tilbagefald.
9. In vitro-fremgangsmåde til sensibilisering af en cancercelle over for en ty-rosinkinasehæmmer, der er selektiv eller specifik for EGFR, hvilken fremgangsmåde omfatter at bringe cellen i kontakt med et miR-7-miRNA eller en prækursor deraf, hvor prækursoren vælges fra gruppen bestående af hsa-miR-7-1, hsa-miR-7-2 og hsa-miR-7-3, og hvor cancercellen udtrykker EGFR.
10. In wiro-fremgangsmåde ifølge krav 9, hvor sensibiliseringen gør cellen sårbar over for en cytostatisk eller cytotoksisk dosis af tyrosinkinasehæmmeren, der er lavere end den cytostatiske eller cytotoksiske dosis, der er nødvendig ved fravær af miRNA'et.
11. In wfro-fremgangsmåde ifølge krav 9 eller 10, hvor tyrosinkinasehæmmeren vælges fra gruppen bestående af erlotinib og AG1478.
12. In wYro-fremgangsmåde ifølge et af kravene 9 til 11, hvor miR-7-miRNA er hsa-miR-7 og omfatter nukleotidsekvensen ifølge SEQ ID NO:1.
13. In wfro-fremgangsmåde ifølge et af kravene 9 til 12, hvor miR-7-miRNA-prækursoren omfatter en sekvens ifølge en af SEQ ID NO:2 til 4.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2009905758A AU2009905758A0 (en) | 2009-11-24 | Method of Modulating Epidermal Growth Factor (EGF) Ligands | |
| PCT/AU2010/001578 WO2011063456A1 (en) | 2009-11-24 | 2010-11-24 | Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2521555T3 true DK2521555T3 (da) | 2017-01-09 |
Family
ID=44065735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10832418.7T DK2521555T3 (da) | 2009-11-24 | 2010-11-24 | Fremgangsmåder og sammensætninger til forøgelse af følsomheden over for tyrosinkinasehæmmere |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20130090366A1 (da) |
| EP (2) | EP2521555B1 (da) |
| JP (2) | JP2013511560A (da) |
| CN (2) | CN102762213A (da) |
| AU (2) | AU2010324530B2 (da) |
| CA (2) | CA2781572A1 (da) |
| DK (1) | DK2521555T3 (da) |
| ES (1) | ES2608923T3 (da) |
| WO (2) | WO2011063455A1 (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2281889B1 (en) | 2004-11-12 | 2014-07-30 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
| EP3369817A1 (en) * | 2010-07-06 | 2018-09-05 | InteRNA Technologies B.V. | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma , or in diseases or conditions with activated braf pathway |
| JP6342329B2 (ja) * | 2011-11-25 | 2018-06-13 | アンテグラジャンＩｎｔｅｇｒａｇｅｎ | Ｅｇｆｒ阻害剤による治療に対する応答性を予測するための方法 |
| FR2984168B1 (fr) * | 2011-12-19 | 2019-07-05 | Chanel Parfums Beaute | Micro-rna pour leur utilisation dans la pigmentation |
| US20150126621A1 (en) * | 2012-05-15 | 2015-05-07 | New York University | METHOD FOR PREDICTING RECURRENCE OF MELANOMA USING miRNA ALTERATIONS |
| IN2015DN04209A (da) * | 2012-10-18 | 2015-10-16 | Univ Western Australia | |
| US20140308274A1 (en) * | 2013-03-15 | 2014-10-16 | Mirna Therapeutics, Inc. | Combination cancer treatments utilizing synthetic oligonucleotides and egfr-tki inhibitors |
| EP2968567A2 (en) * | 2013-03-15 | 2016-01-20 | Mirna Therapeutics, Inc. | Combination cancer treatments utilizing micrornas and egfr-tki inhibitors |
| EP3027225B1 (en) | 2013-07-31 | 2021-03-24 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating thermogenesis using transforming growth factor alpha |
| CN108537001B (zh) * | 2018-04-12 | 2021-06-01 | 华中科技大学鄂州工业技术研究院 | 一种预测用于治疗肝癌的特异性治疗药物的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7893034B2 (en) * | 2004-09-02 | 2011-02-22 | Yale University | Regulation of oncogenes by microRNAs |
| EP2281889B1 (en) * | 2004-11-12 | 2014-07-30 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
| ES2534430T3 (es) * | 2006-08-28 | 2015-04-22 | The University Of Western Australia | Método de modulación de la expresión del receptor del factor de crecimiento epidérmico (EGFR) que implica miARN |
| CN101675165A (zh) * | 2006-12-08 | 2010-03-17 | 奥斯瑞根公司 | Let-7微小rna的功能和靶标 |
| CA2675979A1 (en) * | 2007-01-19 | 2008-07-24 | Bayer Healthcare Llc | Treatment of cancers having resistance to chemotherapeutic agents |
-
2010
- 2010-11-24 US US13/511,183 patent/US20130090366A1/en not_active Abandoned
- 2010-11-24 WO PCT/AU2010/001577 patent/WO2011063455A1/en active Application Filing
- 2010-11-24 US US13/511,181 patent/US9051551B2/en active Active
- 2010-11-24 ES ES10832418.7T patent/ES2608923T3/es active Active
- 2010-11-24 WO PCT/AU2010/001578 patent/WO2011063456A1/en active Application Filing
- 2010-11-24 DK DK10832418.7T patent/DK2521555T3/da active
- 2010-11-24 CN CN2010800604001A patent/CN102762213A/zh active Pending
- 2010-11-24 AU AU2010324530A patent/AU2010324530B2/en not_active Ceased
- 2010-11-24 JP JP2012540229A patent/JP2013511560A/ja active Pending
- 2010-11-24 JP JP2012540228A patent/JP2013511559A/ja active Pending
- 2010-11-24 CA CA2781572A patent/CA2781572A1/en not_active Abandoned
- 2010-11-24 CA CA2781571A patent/CA2781571A1/en not_active Abandoned
- 2010-11-24 EP EP10832418.7A patent/EP2521555B1/en active Active
- 2010-11-24 CN CN2010800604035A patent/CN102762214A/zh active Pending
- 2010-11-24 AU AU2010324529A patent/AU2010324529A1/en not_active Abandoned
- 2010-11-24 EP EP10832417.9A patent/EP2504014A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| ES2608923T3 (es) | 2017-04-17 |
| EP2521555B1 (en) | 2016-09-28 |
| EP2504014A1 (en) | 2012-10-03 |
| US9051551B2 (en) | 2015-06-09 |
| JP2013511559A (ja) | 2013-04-04 |
| US20130090366A1 (en) | 2013-04-11 |
| CA2781572A1 (en) | 2011-06-03 |
| AU2010324529A1 (en) | 2012-07-19 |
| JP2013511560A (ja) | 2013-04-04 |
| CN102762213A (zh) | 2012-10-31 |
| AU2010324530A1 (en) | 2012-07-19 |
| CA2781571A1 (en) | 2011-06-03 |
| WO2011063455A1 (en) | 2011-06-03 |
| WO2011063456A1 (en) | 2011-06-03 |
| CN102762214A (zh) | 2012-10-31 |
| EP2521555A1 (en) | 2012-11-14 |
| EP2521555A4 (en) | 2013-08-07 |
| EP2504014A4 (en) | 2013-04-17 |
| US20130116299A1 (en) | 2013-05-09 |
| AU2010324530B2 (en) | 2016-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2521555T3 (da) | Fremgangsmåder og sammensætninger til forøgelse af følsomheden over for tyrosinkinasehæmmere | |
| Yan et al. | miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer | |
| US9795626B2 (en) | Cancer therapy using miRNAs | |
| WO2014046617A1 (en) | Compositions and methods for treating cancer | |
| US20190300882A1 (en) | Methods of treating neuroblastoma and reagents therefor | |
| EP2760457A1 (en) | Methods and pharmaceutical compositions for treating cancer | |
| US11759530B2 (en) | TKI permeability enhancers | |
| CA2889020A1 (en) | Treatment of metastatic breast cancer | |
| KR100694804B1 (ko) | 작은 헤어핀 ｒｎａ 분자를 포함하는 자궁 내막암 치료또는 예방용 조성물 및 그를 이용한 자궁 내막암 치료 또는예방 방법 | |
| US20160244758A1 (en) | Targeting glioma stem cells by sequence-specific functional inhibition of pro-survival oncomir-138 | |
| US11859183B2 (en) | Treatment of tumors with miRNA targeting CDK4/CDK6 | |
| Maritz | Repression of telomerase components in isogenic normal, immortal and tumorigenic cells | |
| Mody | Investigation of Micro-RNA-based Approaches to Overcome Epithelial-Mesenchymal Transition in Pancreatic Cancer | |
| JP2013018754A (ja) | 悪性胸膜中皮腫治療剤 | |
| KR20120005240A (ko) | 제2알데하이드 탈수소효소의 발현을 억제하는 인공 마이크로 ｒｎａ 및 이의 이용 | |
| D’Andrea et al. | Genetic and functional dissection of the miR-17∼ 92 cluster of miRNAs | |
| WO2008052238A1 (en) | Treatment of urological cancer | |
| Kinsella | The investigation of targets for therapy in brain tumours | |
| JP2018061481A (ja) | 癌の予後マーカー及びその使用 |